Quick and comprehensive information on psychotropic drugs for children and adolescents.

• Accurate and up-to-date
• Specific to children and adolescents
• Charts and tables help decision-making
• Icons and full color

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more—all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• Clearly written patient and caregiver information sheets for download as printable PDF files

This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.

• Drugs for ADHD thoroughly revised and updated
• Antipsychotics with many changes and additions, including fully revised lab tests/monitoring
• Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations
• Hypnotics completely revised
• Mood stabilizers fully revised and a new toxicity comparison table added
• Drugs of abuse and treatment of substance use disorder comprehensively revised
• New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use, and irritability of autism
• New agents include: TGAs N-arylpiperazine (brexpiprazole) and phenylpiperazine (cariprazine), hypnotics orexin receptor antagonist (hypnotic suvorexant) and selective melatonin agonist (tasimelteon), antidepressant bisarylsulfanyl amine (vortioxetine)
• New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR,Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Som-Pam, Tegretol (liquid), Trintellix, Versacolz, Vraylar, Vyvanse, Zelapar, Zenzedi

Dean Elbe's profile page

Tyler R. Black's profile page

Ian R. McGrane's profile page

Ric M. Procyshyn's profile page